Although autophagy-the degradation of cytosolic components in lysosomes-has been known for more than five decades, its importance in the central nervous system, and in neurons in particular, has only recently been demonstrated [1] [2] [3] [4] . The explosion of information in the field of autophagy 3 is leading to a better understanding of classic neuronal disorders-in particular, those dealing with protein mishandling and problems in cellular quality control.
Although autophagy-the degradation of cytosolic components in lysosomes-has been known for more than five decades, its importance in the central nervous system, and in neurons in particular, has only recently been demonstrated [1] [2] [3] [4] . The explosion of information in the field of autophagy 3 is leading to a better understanding of classic neuronal disorders-in particular, those dealing with protein mishandling and problems in cellular quality control.
As the field advances, some chapters in our understanding of autophagy are finally reaching closure. These include the initial controversy over whether or not autophagy even occurs in neurons: neuronal accumulation of autophagosomes has been described in multiple brain disorders (reviewed in refs. 1, 5, 6) , and it is clear that neurons have the machinery and molecular components required for conducting autophagy. Neurodegeneration and protein inclusions have been described in mouse models incompetent to perform autophagy in neuronal tissues 7, 8 , making a strong case for a critical role of autophagy in maintenance of neuronal homeostasis and protein quality control in neurons. More recent studies using similar genetic approaches have now confirmed an essential function of autophagy in neuronal development and remodeling [9] [10] [11] [12] .
In contrast, other topics, such as the nature of the autophagic defect in different neurodegenerative disorders, are now making headlines, and many studies and resources are dedicated to their detailed dissection. This review will focus on the different types of autophagic dysfunction in neurodegeneration and the importance of identifying the autophagic step(s) altered in each particular disorder for therapeutic purposes.
Autophagic pathways in neurons
Cellular quality control through autophagy is particularly relevant in neurons, where the total content of altered proteins and damaged organelles cannot be reduced by redistribution to daughter cells by means of cell division. Neuronal surveillance mechanisms must identify these malfunctioning structures and assure their autophagic degradation before their intracellular buildup gives rise to neurotoxicity 5, 6 . Delivery of autophagic subcellular components to the damaged structures must accommodate the unique neuronal architecture, whereby the cytoplasm can extend long distances through the many projections from the cellular body and accommodate the dynamic traffic to and from polarized neuronal projections. Besides neuronal homeostasis, autophagy is also used for the continuous remodeling of neuronal terminals that is required to support neuronal plasticity [9] [10] [11] [12] . On the basis of these prior observations, it is not surprising that alterations in the autophagic system would be intimately linked to different neuronal diseases.
The first clue of altered autophagy in different neurodegenerative settings is often an abnormal number of autophagosomes in the affected neurons [13] [14] [15] . However, expansion of this autophagic compartment could come from the impairment in any of the several steps of autophagy, and it only provides information on macroautophagy, one of the subtypes of autophagy. In fact, the term autophagy refers to the degradation of cytosolic components in lysosomes independently of the mechanism by which the degraded cargo is delivered to the lysosomal compartment. In most mammalian cells, delivery occurs by three different means that distinguish the subtype of autophagy: macroautophagy, microautophagy and chaperone-mediated autophagy (CMA). The characteristics, regulation and main molecular components of these autophagic pathways have been reviewed in detail elsewhere [1] [2] [3] . Briefly, macroautophagy and microautophagy involve the direct sequestration of whole areas of the cytosol by invaginations at the lysosomal membrane (in the case of microautophagy), or by a membrane that seals to form a double-membraned vesicle, or autophagosome (in macroautophagy). Microautophagic vesicles at the lysosomal membrane 'pinch off ' into the lysosomal lumen, and cargo is degraded by the lysosomal hydrolases upon digestion of the vesicles' limiting membrane 16 . In the case of macroautophagy, fusion between autophagosomes and lysosomes mediates the delivery of the autophagic cargo into the lysosomal lumen 1,2 . In the third common type of autophagy, CMA, cargo is not sequestered but is instead selectively recognized by a complex of cytosolic chaperones that mediates its delivery to a receptor at the lysosomal membrane 17, 18 . Cargo gains access to 8 0 6 VOLUME 13 | NUMBER 7 | JULY 2010 nature neuroscience r e v i e w the lysosomal lumen through a translocation complex, thus limiting CMA to soluble proteins that can undergo complete unfolding. All three autophagic pathways usually coexist in the same cell, and alterations in both macroautophagy and CMA have recently been associated to specific neurodegenerative disorders 17 .
The when and where of the macroautophagic halt The detailed molecular characterization of macroautophagy and the development of probes to track and methods to modulate this process have been instrumental in our understanding of the physiological functions of this pathway 3 . These advances have facilitated the identification of autophagic malfunction in many human disorders (a complete description of the pathophysiology of macroautophagy can be found in refs. 1, 19, 20) , including a growing number of neurological disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis (ALS) 13, 14, [21] [22] [23] [24] [25] [26] . Different findings in recent years have helped to consolidate a connection between macroautophagy and neurodegenerative disorders and have propelled the current interest in this topic. For example, aggregates formed by some pathogenic proteins have proven amenable to degradation by macroautophagy 22, 27 . In addition, pharmacological upregulation of macroautophagy has been shown effective in reducing neuronal aggregates and slowing the progression of neurological symptoms in fly and mouse models of Huntington's disease 28 . These findings have generated a justifiable level of optimism and have led to the idea that upregulation of macroautophagy might represent a plausible therapeutic intervention in these disorders. However, recent studies have added a note of caution concerning the applicability of macroautophagy upregulation as a generalized treatment. For example, inhibition, rather than stimulation, of macroautophagy increases neuronal survival in some pathological conditions showing high content of neuronal autophagic vacuoles, such as ischemic stroke 15, [29] [30] [31] . How can blocking macroautophagy be beneficial when it is the only pathway that can eliminate the pathogenic proteins once they form aggregates? The main reason is that an increase in autophagosomes is not always indicative of an increase in autophagy-at least, not of more degradation through autophagy. Cells could contain more autophagosomes when macroautophagy is upregulated (more formation of autophagosomes) but also when clearance of autophagosomes is impaired (less fusion with and degradation of autophagosomes by lysosomes) 21, 32 . Understanding the nature of the changes in the autophagic pathway leading to autophagic malfunction has now become a priority.
Because autophagic degradation involves multiple steps, we discuss the consequences of alterations in each of the different steps of macroautophagy in the context of different neurodegenerative disorders (Fig. 1) .
Induction of autophagy. Formation of the isolation membrane of the autophagosome, called the phagophore, is the earliest event in macroautophagy. Discrete regions in the endoplasmic reticulum (the omegasomes) may serve as the nucleation site in mammalian cells 33 where components required for the formation of the isolation membrane (Atg or autophagy-related proteins) are recruited. For the most part, Atg proteins that participate in the formation of the isolation membrane-the Atg5-Atg12-Atg16 complex, the LC3-phosphatidylethanolamine protein-to-lipid conjugation complex and their corresponding conjugating enzymes 34 -do not seem to exist in limiting amounts inside cells. Although knockouts and knockdowns of components such as Atg5 or Atg7 have been extensively used to suppress macroautophagy 7, 8 , pathological conditions arising by depletion of these factors in mammals have yet to be identified. However, decreases in effector Atg proteins has been reported in the brain of aging flies, and restoration of proteins to their youthful levels delays neurodegeneration and extends the flies' lifespan 35 . More limiting seems to be the class III phosphatidylinositol-3-kinase complex (PI3K) that mediates the nucleation of the phagophore. Three proteins-Vps15, Vps34 and beclin-1-are essential components of this complex, and their recruitment to the phagophore initiates the nucleation process 36, 37 (Fig. 1, panel 1 ). Cellular levels of beclin-1 have often been correlated with autophagic activity, and heterozygous deletion of beclin-1 leads to neurodegeneration 9 . In contrast, the increases in beclin-1 described in different neurodegenerative disorders often reflect neuronal upregulation of macroautophagy in response to pathogenic proteins or neuronal injury 38 . The limiting nature of beclin-1 could be behind the aggravating effect of aging in neurodegeneration, as lower levels of beclin-1 have been reported in brains from old individuals 39 . However, cellular availability of beclin-1, rather than just total cellular abundance, might hold the key to defective autophagy in different pathologies. Integration of beclin-1 into the nucleation complex is negatively regulated by its binding to Bcl-2 (ref. 40) , and this itself is modulated through post-translational modifications of beclin-1 (ref. 41) . It is thus conceivable that changes in the enzymes that mediate these post-translational modifications or r e v i e w in the cellular subcompartmentalization of beclin-1 could underlie autophagic failure in some neurodegenerative settings 12, 37, 40, 41 . Macroautophagy is negatively regulated by a second major kinase complex, the serine/threonine protein kinase mTOR (mammalian target of rapamycin) 42 (Fig. 1, panel 2) . Chemical inhibition of mTOR, often used to activate macroautophagy, was indeed the first autophagic manipulation shown to slow the progress of neurodegeneration 28 , and sequestration of mTOR in protein aggregates has been proposed to mediate upregulation of macroautophagy in animal models of Huntington's disease 28 . However, whether or not changes in the autophagic targets downstream of mTOR 43 occur in neurodegeneration requires further investigation.
Cargo sequestration. Although macroautophagy was previously considered an 'in-bulk' process, overwhelming evidence now supports selectivity in the sequestration of autophagic cargo 44, 45 ( Fig. 1, panel 3) . Recognition of certain post-translational modifications, often polyubiquitination, by molecules that bind both cargo and components of the autophagic machinery mediates this selectivity 45, 46 . p62, the first cargo-recognizing molecule identified, binds preferentially to a particular type of ubiquitin linkage (Lys63) on the surface of protein aggregates and brings autophagosome formation to these aggregates through its interaction with LC3 47, 48 . p62 has turned out to be a complex molecule that not only participates in autophagic clearance of aggregates but also modulates aggregate formation and regulates stress-response genes. These other functions of p62 could explain in part why deletion of p62 ameliorates hepatic injury in animals deficient for macroautophagy in liver 49 . This effect is, however, organ specific, because deletion of p62 does not suppress neurodegeneration in neuronal macroautophagy-deficient mice 49 . Cargo recognition by p62 is not limited to protein aggregates but also includes organelles and even pathogens 50, 51 . Ubiquitin is also the recognition signal for NBR1 and NDP52, recently identified p62-like molecules. The targeted cargo in the case of NBR1 is limited to proteins 52 , whereas NDP52 recognizes ubiquitin-coated bacteria inside human cells 53 .
Inefficient recognition of aggregate proteins by macroautophagy, which depends on the nature of the aggregate protein, has been described in an aggregate-prone experimental setting 54 . For example, whereas cytosolic inclusions of α-synuclein, synphilin-1, mutant tau or huntingtin are readily amenable to macroautophagy removal, inclusions of p38 and desmin persist in the cytosol even when macroautophagy is maximally activated 54 . Unexpectedly, p62 is present in both types of aggregates, suggesting that p62 is necessary but not sufficient to bring together the autophagy machinery and activate autophagic clearance. Intrinsic properties of the aggregating proteins, specific post-translational modifications or changes in their interaction with cargo-recognizing molecules could determine amenability to autophagic clearance. In this respect, acetylation has recently shown to modulate autophagic clearance, although with different effect, depending on the substrate protein. Thus, whereas acetylation of a fragment of huntingtin facilitates its autophagic clearance 55 , acetylation of ataxin-7 prevents its autophagy-mediated turnover 56 .
Changes not only in the substrates but also in the autophagic system itself could lead to inefficient cargo recognition. In fact, a paradoxical decrease in macroautophagy-mediated degradation, despite proper formation and clearance of autophagosomes, has recently been identified in different Huntington's disease models 57 . Analysis of these autophagosomes reveals a marked decrease in their cargo content, giving the impression of 'empty' autophagosomes. Because the failure to recognize cargo is not limited to a particular cytosolic component, it is plausible that a primary defect in the autophagosome membrane is behind the observed failure.
Autophagosome clearance. Degradation of the sequestered cargo only occurs when autophagosomes fuse to lytic compartments (that is, lysosomes or endosomes). In contrast to our understanding in yeast, where a subset of SNARE proteins has been shown to mediate fusion of autophagosomes to the vacuole, the components that participate in fusion of mammalian autophagosomes to lysosomes or endosomes are poorly characterized 2 . So far, only the Rab7 GTPase and the SNARE Vtilb have been shown necessary for mammalian autophagic fusion, although the participation of other Rab proteins and several vacuolarassociated SNARE proteins has also been proposed 2 . In addition to these components in the membrane of autophagosomes and lysosomes, autophagosome clearance also involves the participation of the cellular cytoskeleton and cytosolic modulators [1] [2] [3] [4] .
Alterations in autophagosome clearance have become a common theme for a growing number of neurodegenerative disorders. The distinctive characteristic of the affected neurons is an increase in the number of autophagic vacuoles that does not associate with increased autophagic flux. Defects can originate from the inability to mobilize autophagosomes from their site of formation toward lysosomal or endosomal compartments, decreased fusion between their membranes or decreased proteolysis inside lysosomes (Fig. 1, panel 4) . For example, changes in the properties of microtubules, motorassociated proteins such as dynein, dynactin or tubulin deacetylases such as HDAC6 have been described in different neurodegenerative settings with altered macroautophagy [58] [59] [60] [61] [62] . Cells defective in HDAC6 also show a primary defect in vesicular fusion that is independent of microtubules, involving instead the actin cytoskeleton 63 . Formation of actin bundles at the surface of autophagosomes is required for fusion 63 , but it is only needed for quality-control autophagy and not for starvation-induced autophagy. This finding is particularly interesting because it supports the existence of mechanistic differences in the way macroautophagy is performed in response to different stimuli.
In some instances, autophagosome-lysosome fusion occurs but degradation of the delivered cargo is incomplete or nonexistent (Fig. 1, panel 5) . Changes in the lysosomal lumen, such as reduced lysosomal acidification, accumulation of undigested by-products and decreased content or activity of lysosomal hydrolases, have been described behind such degradative failure. In this respect, many conditions that fall into the category of lysosomal storage disorders-a group of diseases characterized by deficit or malfunctioning of specific lysosomal enzymes-have an associated deficient autophagic clearance that could explain, at least in part, the neurological symptoms often associated with these disorders [64] [65] [66] . A primary defect in lysosomal acidification has also been recently identified in forms of Alzheimer's disease resulting from alterations in presenilin-1 (ref. 67 ). The lower proteolytic capability of these lysosomes leads to the massive neuronal accumulation of undegraded autophagosomes observed in the Alzheimer's disease-affected brain at advanced stages.
Consequences of autophagic failure
Defective autophagy has different effects in cellular homeostasis depending on the autophagic step primarily affected. Failure to induce autophagosome formation results in cytosolic persistence of unsequestered cargo, which could promote aggregation of other intracellular components (acting as an aggregation 'seed') or become a source of toxic products (for example, damaged mitochondria may produce reactive oxygen species). Accumulation of protein 8 0 8 VOLUME 13 | NUMBER 7 | JULY 2010 nature neuroscience r e v i e w aggregates, higher content of abnormal, nonfunctional mitochondria, deformities of the endoplasmic reticulum, and an increase in the number and size of lipid droplets have been described in different conditional ATG knockout mice 7, 8, 10 .
When autophagic failure originates from inefficient cargo recognition, the extent of cellular impairment depends on whether recognition problems are limited to a particular type of cargo or they affect sequestration of all intracellular components. The consequences of general failure to recognize autophagic cargo are the same as those when autophagy induction fails, described above. Because autophagosomes are still formed, however, bulk removal of randomly sequestered soluble components is often preserved 57 . When only a particular type of cargo escapes targeted autophagy, the cellular consequences depend on the effects that accumulation of that cargo can cause. For example, inability to recognize mitochondria results in poor mitochondrial turnover, alterations in mitochondria dynamics and the increase in oxidative damage associated with mitochondria malfunctioning 68, 69 .
In circumstances when the autophagic defect originates from poor clearance of autophagosomes, accumulation of autophagosomes inside cells can be detrimental for neurons. Although autophagosome formation would at least prevent the undesirable effects of unsequestered cytosolic cargo, this expansion of the autophagic compartment can interfere with intracellular trafficking 70 . Furthermore, autophagosomes can become a source of cytotoxic products. For example, in cellular and animal models of Alzheimer's disease, the presence of the amyloid precursor protein (APP) in the accumulating autophagosomes, along with the protease complex responsible for its cleavage into the pathogenic peptide β1-42, converts autophagosomes into an endogenous source of this pathogenic product 70 . Lastly, autophagic compartments that persist longer than usual in the cytosol can become leaky, and if leakage occurs after lysosomal fusion, the release of lysosomal enzymes often activates cell death 71 .
Looking for another way out during macroautophagic failure Current pharmacological options to modulate autophagy in vivo by directly acting on autophagic components are still very limited. Further expansion of the therapeutic options could be attained through a better understanding of the compensatory mechanisms and autophagic alternatives that are activated by cells when autophagy fails. In recent years, it has become evident that macroautophagy acts in a coordinated manner with other cellular proteolytic mechanisms 72, 73 . The first insights into this coordinated function were obtained by analyzing the consequences of blocking other proteolytic systems on macroautophagy and vice versa (Fig. 2) . Cells respond to blockage of CMA by activating macroautophagy in a constitutive manner 72 . Although the two pathways are not redundant, compensatory activation of macroautophagy in basal conditions preserves homeostasis in cells with compromised CMA 72 . Likewise, CMA is upregulated in response to macroautophagy blockage 73 . Cross-talk between these pathways is of particular interest in neurodegeneration because primary blockage of CMA has been identified in Parkinson's disease models and certain tauopathies [74] [75] [76] . Pathogenic variants of α-synuclein and truncated forms of tau interfere with normal functioning of the CMA translocation complex, thus reducing degradation of other CMA substrates (damaged and misfolded cytosolic proteins), which accumulate in the cytosol and compromise neuronal function [74] [75] [76] . The activation of macroautophagy observed in Parkinson's disease 24 may be secondary to CMA blockage and could help alleviate these conditions. Also of increasing interest are the connections between macroautophagy and other, nonautophagic lysosomal pathways such as endocytosis (Fig. 2) . Disrupted formation of multivesicular bodies due to ESCRT-III dysfunction in the membrane of late endosomes leads to reduced autophagic flux and autophagosome accumulation in models of frontotemporal dementia 77, 78 . Additional genetic studies have revealed that other components essential for endosome biogenesis (namely, ESCRT-I and ESCRT-II, their regulatory ATPase Vps4 and the endosomal kinase Fab1) are all required for autophagy 78 . Disruption of these endosomal proteins leads to accumulation of cytosolic polyubiquitinated pathogenic proteins such as huntingtin or TDP-43 (a component of protein inclusions seen in ALS), as expected from autophagic failure 79, 80 . Functional endosomes are important for autophagosome clearance, likely through the fusion between the two compartments to form amphisomes. Amphisomes are hybrid vesicular compartments that arise from the fusion of autophagosomes with endosomes instead of with lysosomes. Enhanced formation of amphisomes has been demonstrated when autophagosome-lysosome fusion is compromised 81 , which in turn accommodates augmented formation of autophagosomes 82 (Fig. 2) . Figure 2 Cross-talk among macroautophagy and different cellular proteolytic systems. The consequences of macroautophagic blockage on the activity of other autophagic pathways, on endocytosis and on the ubiquitin proteasome system (UPS) and the consequences of changes in these pathways on macroautophagy are depicted. Examples of neurodegenerative disorders for which this cross-talk has been shown to be relevant are indicated in the red boxes and are discussed in more detail in the text. MVB, multivesicular bodies; CMA, chaperone-mediated autophagy; UPS, ubiquitin proteasome system; AD, Alzheimer's disease; HD, Huntington's disease; PD, Parkinson's disease; FTD, frontotemporal dementia; ALS, amyotrophic lateral sclerosis; SMA, spinal muscular atrophy.
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These interactions between the autophagic and endocytic pathways could be especially important in the case of prion diseases because endocytosis is a principal route of cellular entry for pathogenic forms of prion proteins (PrP sc ) 83 . Furthermore, endocytic compartments, specifically multivesicular bodies, can also mediate transmission of the pathogenic protein between cells. Upon fusion of endosomes and plasma membrane, the PrP sc located in the luminal vesicles of multivesicular bodies gains access to the extracellular medium in the form of exosomes 83 . Similar interactions with the endocytic system have been proposed for other pathogenic proteins, such as amyloid-β, α-synuclein and tau proteins, involved in noninfectious neurodegenerative disorders 84 . In theory, conditions that favor endosomal degradation over endosomal recycling should facilitate elimination of the pathogenic proteins by the lysosomal system. In this scenario, enhanced fusion of autophagosomes with endosomes may reroute the endosomal compartments toward lysosomes. Further investigation is necessary to determine whether or not this is the mechanism behind the lower intracellular levels of PrP sc and reduced PrP sc propagation observed upon upregulation of macroautophagy with trehalose and lithium 85 .
The cellular connections of macroautophagy extend beyond the lysosomal system to other proteolytic systems. Special attention has been paid to the interplay between macroautophagy and the ubiquitin proteasome system (UPS) (Fig. 2) (reviewed in ref. 86) . Cells respond to acute proteasome blockage by upregulating macroautophagy 27, 87 , whereas persistent chronic blockage of this protease leads to constitutively upregulated macroautophagy but failure to further activate macroautophagy in response to stress 88 . Chemical upregulation of macroautophagy in mice protects them from the neurodegeneration induced upon inhibition of proteasomes 89 , reinforcing the possible therapeutic implications of this cross-talk. The massive accumulation of polyubiquitinated aggregates resulting from genetic blockage of macroautophagy 7, 8 indicates that polyubiquitinated proteins, initially considered exclusive cargo of the UPS, are also substrates of the autophagic system. However, it remains controversial whether macroautophagy only engulfs these proteins when they are in aggregates or also degrades soluble polyubiquitinated proteins in a selective manner. Differences in the types of ubiquitin linkage may determine delivery to one or another degradative pathway; whereas ubiquitination of Lys48 leads preferentially to UPS degradation, there is growing evidence that Lys63-ubiquitinated proteins may be rerouted to macroautophagy for degradation 48, 90 . A promising possible modulator of the macroautophagy and UPS is p53, a well-characterized UPS substrate that has recently been shown to upregulate macroautophagy 91 . Failure to degrade p53 by the UPS will increase its cytosolic levels, leading to activation of macroautophagy. In return, increased autophagy should facilitate p53 clearance and prevent engagement of the mitochondrial apoptotic pathways downstream of p53 (ref. 91 ). The microtubuleassociated deacetylase HDAC6 also links polyubiquitinated proteins and autophagy, as it has been shown to be essential for rescue of the degeneration associated with proteasome failure in an autophagydependent manner 87 . In contrast, blockage of macroautophagy does not enhance UPS activity but instead compromises its function 92 . This effect seems mediated by p62, a putative substrate of both systems 93 that, when it accumulates in the cytosol owing to impaired macroautophagy, competes with other ubiquitinated proteins for delivery to the proteasome 92 (Fig. 2) .
Connections between macroautophagy and the UPS are not limited to the removal of cytosolic ubiquitinated proteins but also involve removal of organelles. For example, ubiquitination of constituent proteins in the membranes of peroxisomes mediates their macroautophagy 51 . This new connection between ubiquitination and organelle autophagy may be particularly important in Parkinson's disease-affected neurons. In fact, two genes related to familial forms of Parkinson's disease, the ubiquitin ligase parkin and the serine/ threonine kinase PINK1, have recently been implicated in autophagy of dysfunctional mitochondria 68 . PINK1 accumulates selectively on dysfunctional mitochondria and induces translocation of parkin to the depolarized mitochondria. Subsequently, parkin-mediated ubiquitination of mitochondrial proteins by Lys63 and Lys27 linkage favors mitochondrial aggregation and recruitment of p62, which brings along the autophagic machinery 69 . Mutant forms of these proteins disrupt mitophagy at different steps-translocation, aggregation, ubiquitination and autophagic clearance 68, 94 .
Therapeutic considerations for each autophagic failure type Identification of the specific autophagic step(s) affected in the different neuronal pathologies is an important consideration for the future development of therapeutic interventions that depend on modulating autophagy to prevent neuronal degeneration. The nature of the autophagic defect, the cellular response to that defect and elapsed time into the progression of the disease should all be taken into account during the implementation of these therapeutic approaches.
Conditions resulting from hampered macroautophagy induction should benefit from treatments that activate macroautophagy. In contrast, inhibition of autophagy should be remedial when excessive activation of autophagy leads to cytosolic depletion of essential organelles 95 . Autophagy activators may have a limited beneficial effect in neurodegenerative disorders arising from defective cargo recognition. In fact, activation of autophagosome formation may increase the amount of cargo randomly sequestered and degraded through macroautophagy, but the loss of selectivity in recognizing the cargo is likely to decrease the efficiency of the process. A better characterization of cargo-recognition molecules is necessary for the design of molecular interventions aimed at enhancing cargo recognition. Activation of autophagy can become detrimental in the context of the massive accumulation of undegraded autophagic vacuoles observed in many neurodegenerative diseases. In fact, treatments that inhibit autophagosome formation have been shown to improve neuronal viability, at least temporarily, in conditions such as frontotemporal dementia, ischemic injury or Alzheimer's disease, where most of the autophagosome accumulation originates from problems in clearance 21, 77 . The optimal treatment should enhance autophagosome clearance by the lysosomal compartment. Although pharmacological compounds with these effects are as yet unavailable, remarkably good results have been observed with promoting lysosomal biogenesis by overexpression of the transcription factor EB 96 . The new and healthy lysosomes may mediate removal of the accumulated autophagosomes, although it remains unclear for how long and to what extent extra formation of lysosomes can be maintained.
Lastly, an aspect that could offer considerable room for therapeutic manipulation in the future is the increasing number of autophagic variations that coexist in a given cell (Fig. 3) . It has become evident that different mechanisms can lead to formation of autophagosomes, whereas some molecular components once thought to be essential for macroautophagy can be dispensable. As a case in point, we now know that there is mTOR-dependent and mTOR-independent autophagy 46, 97, 98 , noncanonical autophagy that occurs even in the absence of beclin-1 (ref. 99 ) and autophagosome formation even in the absence of Atg5 and Atg7 (ref. 100) (Fig. 3) . An important task in the coming years will be matching these different autophagic variants with the different conditions that result in autophagic activation. The traditional division into basal and starvation-induced macroautophagy has been revised to make room for other cellular events requiring autophagic involvement (Fig. 3) . Basal in-bulk macroautophagy and starvation-induced autophagy still remain at the extremes of this scale, whereas quality-control autophagy and autophagy induced by protein aggregates, organelle stress or pathogen invasion are finding their locations in this classification as their unique properties are becoming apparent. Using alternative macroautophagy variants to compensate for the defective ones could be an exciting therapeutic alternative still unexplored.
